AUS
NZ
UK
CA
USA
IND
_06_16_2026_06_12_08_773360.jpg)
Amgen Inc
Amgen Inc (0R0T) is into the research of biotechnologies specialising in human therapeutics for curing serious ailments in the areas of oncology, cardiovascular diseases and the nervous system.
Recent News
Amgen has abandoned its ongoing research to find drugs for curing Alzheimer, a neurodegenerative disorder, concluding that the expected benefits did not offset the risk for participants. This decision will have adverse effect on patients suffering from neurodegenerative disorder who were on trials. This research assumed that the amyloid plaques (which are responsible for neurodegenerative disorder by having a formation between the nerve cells) formed in the brain could be cleared by the new drug formation. The assumption is now being revisited by many scientists.
Financial Highlights for Q1 FY19
The companyâs total revenues stood at $5.6 billion, unchanged as against Q1 FY18 results. The Company was able to generate $1.7 billion of free cash flow this Q1 as against $2.6 billion in Q1 FY18. The companyâs Operating Margin plunged 4.2 percentage points to 46.8 per cent on GAAP basis. The company declared a dividend of $1.45 per share for Q1 FY19. The companyâs net income stood at $1,992 million in Q1 FY19 as against $2,311 million in Q1 FY18.
Share price performance
Stock's 52 weeks High and Low are USD 210.14 /USD 167.38. On July 18, 2019, Stockâs average traded volume for 5 days was 3,913.60 and 30 days â 6,733.30. The average traded volume for 5 days was down by 41.88 per cent as compared to 30 days average traded volume. The companyâs stock beta was 1.18, reflecting high volatility as compared to the benchmark index. The outstanding market capitalisation was around $108 billion, with a dividend yield of 3.05 per cent.
Gilead Sciences
Gilead Sciences Inc (0QYQ) is into the research of biotechnologies, specialising in developing drugs in the realm of âunmetâ medical need; which refers to an area which has no well-defined method of diagnosis, prevention and cure.
Recent News
Galapagos (Belgian biotech group), along with GILEAD, has entered into an agreement for conducting transformative research. GILEAD will make an equity investment of $1.1 billion and an upfront payment of $3.95 billion. This will enable Gilead to access the companyâs Drug research platform and market outside Europe. This agreement will be valid for a period of 10 years. GILEAD will also benefit from a proven drug discovery platform that the company possesses including innovative compounds.
Financial Highlights for Q1 FY19
The companyâs total product sales for Q1 FY19 were $5.2 billion as against $5.0 billion for the same period in FY18. The companyâs Research and development expenses (R&D) stood at $1,057 million in Q1 FY19 as against $937 million in Q1 FY18. The company had cash balances of $30.1 billion as on March 31, 2019. The companyâs operating cash flow stood at $1.4 billion, and it paid cash dividends of $817 million in Q1 FY19.
Share price performance
Stock's 52 weeks High and Low are USD 79.56 /USD 60.64. On July 18, 2019, Stockâs average traded volume for 5 days was 4,295.80 and 30 days â 13,503.00. The average traded volume for 5 days was down by 68.19 per cent as compared to 30 days average traded volume. The companyâs stock beta was 1.17, reflecting high volatility as compared to the benchmark index. The outstanding market capitalisation was around $85.09 billion, with a dividend yield of 3.04 per cent.
Celgene Corp
Celgene Corporation (0QYA) is into the research of biotechnologies, specialising in drug development for the treatment of cancer and inflammatory diseases. It conducts a clinical trial in areas of inflammatory disorders, tumours and immunology.
Recent news
The expiration date has been extended by Bristol-Myers Squibb for exchanging notes issued by Celgene Corporation to the tune of $19,850,000,000 and will be replaced by new notes which will be issued by Bristol-Myers Squibb Company.
The company announced its merger with the pharmaceutical giant Bristol-Myers Squibb in January which shall be completed by the end of this financial year.
Financial Highlights for Q1 FY19
The companyâs net product sales stood at $4,024 million in Q1 FY19 as against $3,531 million in Q1 FY18. The companyâs total revenue stood at $4,025 million in Q1 FY19 as against $3,538 million in Q1 FY18. The companyâs Research and development costs were a tad lower ($1,216 million) in Q1 FY19 as against $2,203 million in Q1 FY18. The companyâs net income stood at $1,545 million in Q1 FY19 as against $846 million in Q1 FY18.
Share price performance
Stock's 52 weeks High and Low are USD 98.91 /USD 60.92. On July 18, 2019, Stockâs average traded volume for 5 days was 43,839.20 and 30 days â 23,525.30. The average traded volume for 5 days was up by 86.35 per cent as compared to 30 days average traded volume. The companyâs stock beta was 1.46, reflecting high volatility as compared to the benchmark index. The outstanding market capitalisation was around $64.09 billion.
Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals (0QZU) is a biopharmaceutical company which focuses on drug development of serious diseases, for instance, cystic fibrosis.
Financial Highlights for Q1 FY19
The companyâs revenue stood at $858,435 thousand for the period as against $640,799 thousand in Q1 FY18. The companyâs net income stood at $268,631 thousand in Q1 FY19 as against $ 227,301 thousand in Q1 FY18. The basic EPS stood at $1.05, and diluted EPS stood at $1.03 in Q1 FY19.
Share price performance
Stock's 52 weeks High and Low are USD 193.32 /USD 156.50. On July 18, 2019, Stockâs average traded volume for 5 days was 2,213.80 and 30 days â 5,570.77. The average traded volume for 5 days was down by 60.26 per cent as compared to 30 days average traded volume. The companyâs stock beta was 1.41, reflecting high volatility as compared to the benchmark index. The outstanding market capitalisation was around $45.37 billion.
Illumina Inc
Illumina Inc (0J8Z) is a biopharmaceutical company which provides solutions for genetic health analysis and reproductive health.
Recent News
Genomics Accelerator from Illumina reaches Cambridge (UK). This will lead to the global expansion of the company. The accelerator is focused on creating an ecosystem for the genomics industry.
Financial highlights for Q1 FY19
The companyâs revenue stood at $846 million for the period as against $782 million in Q1 FY18; a rise of 8 per cent this time. The companyâs Cash flow from operations stood at $198 million as against $255 million in Q1 FY18. The companyâs Gross margin in Q1 FY19 was 69.1 per cent as against 68.8 per cent in Q1 FY18.
Share price performance
Stock's 52 weeks High and Low are USD 378.02 /USD 271.57. On July 18, 2019, Stockâs average traded volume for 5 days was 3,246.40 and 30 days â 5,712.27. The average traded volume for 5 days was down by 43.17 per cent as compared to 30 days average traded volume. The companyâs stock beta was 1.09, reflecting high volatility as compared to the benchmark index. The outstanding market capitalisation was around $44.53 billion.
Biogen Inc
Biogen Inc (0R1B) is a biopharmaceutical company which focuses on therapy development for patients with rare neurological, autoimmune diseases.
Financial highlights for FY18
The companyâs revenue stood at $13,453 million in FY18 as against $12,274 million in FY17. The companyâs net cash flow from operations stood at $6.2 billion this year. The companyâs GAAP diluted earnings per share stood at $21.58 in FY18, which were 81 per cent higher from the previous year. The companyâs Non-GAAP diluted earnings per share surged by 20 per cent in FY18 from the previous year, amounted to $26.20.
Share price performance
Stock's 52 weeks High and Low are USD 385.61 /USD 216.27. On July 18, 2019, Stockâs average traded volume for 5 days was 23,155.00 and 30 days â 10,336.40. The average traded volume for 5 days was up by 124.01 per cent as compared to 30 days average traded volume. The companyâs stock beta was 0.99, it was as volatile as the benchmark index. The outstanding market capitalisation was around $44.49 billion.
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc (0R2M) is a biopharmaceutical company that develops drugs for eye diseases, high low-density lipoprotein (LDL) cholesterol, rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and contagious diseases.
Financial highlights for FY18
The companyâs revenue stood at $6.7Â billion this year, which was 14 per cent higher from FY17. 33 per cent of the revenues were reinvested in R&D efforts. The companyâs GAAP net income was $2.4Â billion in FY18 as against $1.2Â billion in FY17. The company had cash balances of $4.6Â billion this year.
Share price performance`
Stock's 52 weeks High and Low are USD 436.24 /USD 290.19. On July 18, 2019, Stockâs average traded volume for 5 days was 1,217.40 and 30 days â 2,153.37. The average traded volume for 5 days was down by 43.47 per cent as compared to 30 days average traded volume. The companyâs stock beta was 1.15, reflecting high volatility as compared to the benchmark index. The outstanding market capitalisation was around $32.36 billion.
